Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9066674 | 0.84 | ATM (0.74) | ATMTSHRL3MBTL1KMT2AMEN1 | |
| SCHEMBL1859129 | 0.82 | GABBR2 (0.52) | TSHRKMT2ASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL8431654 | 0.80 | L3MBTL1 (0.74) | ATMTSHRL3MBTL1KMT2AMEN1 | |
| SCHEMBL16616451 | 0.79 | ATM (0.68) | ATMTSHRL3MBTL1KMT2AMEN1 | |
| SCHEMBL28114650 | 0.77 | ATM (0.66) | ATMTSHRL3MBTL1KMT2AMEN1 | |
| SCHEMBL12158645 | 0.77 | ATM (0.66) | ATMTSHRL3MBTL1KMT2AMEN1 | |
| SCHEMBL2581702 | 0.77 | ATM (0.66) | ATMTSHRL3MBTL1KMT2AMEN1 | |
| SCHEMBL27509017 | 0.77 | GABBR2 (0.47) | TSHRKMT2ASMN1; SMN2ALDH1A1NPSR1 | |
| SCHEMBL2215724 | 0.76 | GABBR2 (0.42) | SMN1; SMN2ALDH1A1NPSR1LMNAMAPK1 | |
| SCHEMBL22607275 | 0.76 | L3MBTL1 (0.69) | ATMTSHRL3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299491-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | AMGEN INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20200216446-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299491-B2 | Synthesis of key intermediate of KRAS G12C inhibitor compound | KRAS, NRAS, HRAS | ATM 1829/4885TSHR 4245/4885L3MBTL1 3019/4885 |
| US-20200216446-A1 | SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, HRAS | ATM 1829/4885TSHR 4245/4885L3MBTL1 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.